Caveolin-1/-3: therapeutic targets for myocardial ischemia/reperfusion injury
- PMID: 27282376
- DOI: 10.1007/s00395-016-0561-6
Caveolin-1/-3: therapeutic targets for myocardial ischemia/reperfusion injury
Abstract
Myocardial ischemia/reperfusion (I/R) injury is a major cause of morbidity and mortality worldwide. Caveolae, caveolin-1 (Cav-1), and caveolin-3 (Cav-3) are essential for the protective effects of conditioning against myocardial I/R injury. Caveolins are membrane-bound scaffolding proteins that compartmentalize and modulate signal transduction. In this review, we introduce caveolae and caveolins and briefly describe the interactions of caveolins in the cardiovascular diseases. We also review the roles of Cav-1/-3 in protection against myocardial ischemia and I/R injury, and in conditioning. Finally, we suggest several potential research avenues that may be of interest to clinicians and basic scientists. The information included, herein, is potentially useful for the design of future studies and should advance the investigation of caveolins as therapeutic targets.
Keywords: Cardioprotection; Caveolins; Myocardial ischemia.
Similar articles
-
Effect of ischemia reperfusion injury and epoxyeicosatrienoic acids on caveolin expression in mouse myocardium.J Cardiovasc Pharmacol. 2013 Mar;61(3):258-63. doi: 10.1097/FJC.0b013e31827afcee. J Cardiovasc Pharmacol. 2013. PMID: 23403888
-
Helium postconditioning regulates expression of caveolin-1 and -3 and induces RISK pathway activation after ischaemia/reperfusion in cardiac tissue of rats.Eur J Pharmacol. 2016 Nov 15;791:718-725. doi: 10.1016/j.ejphar.2016.10.012. Epub 2016 Oct 11. Eur J Pharmacol. 2016. PMID: 27742593
-
Exendin-4 ameliorates cardiac ischemia/reperfusion injury via caveolae and caveolins-3.Cardiovasc Diabetol. 2014 Sep 7;13:132. doi: 10.1186/s12933-014-0132-9. Cardiovasc Diabetol. 2014. PMID: 25194961 Free PMC article.
-
Pathophysiology and molecular mechanism of caveolin involved in myocardial protection strategies in ischemic conditioning.Biomed Pharmacother. 2022 Sep;153:113282. doi: 10.1016/j.biopha.2022.113282. Epub 2022 Jun 21. Biomed Pharmacother. 2022. PMID: 35750009 Review.
-
Caveolin-3: therapeutic target for diabetic myocardial ischemia/reperfusion injury.Mol Med. 2025 Feb 26;31(1):80. doi: 10.1186/s10020-025-01117-5. Mol Med. 2025. PMID: 40012041 Free PMC article. Review.
Cited by
-
CAV3 alleviates diabetic cardiomyopathy via inhibiting NDUFA10-mediated mitochondrial dysfunction.J Transl Med. 2024 Apr 26;22(1):390. doi: 10.1186/s12967-024-05223-6. J Transl Med. 2024. PMID: 38671439 Free PMC article.
-
Low Pre-Transplant Caveolin-1 Serum Concentrations Are Associated with Acute Cellular Tubulointerstitial Rejection in Kidney Transplantation.Molecules. 2021 Apr 30;26(9):2648. doi: 10.3390/molecules26092648. Molecules. 2021. PMID: 33946587 Free PMC article.
-
Transduced Tat-aldose Reductase Protects Hippocampal Neuronal Cells against Oxidative Stress-induced Damage.Exp Neurobiol. 2019 Oct 31;28(5):612-627. doi: 10.5607/en.2019.28.5.612. Exp Neurobiol. 2019. PMID: 31698553 Free PMC article.
-
Caveolin-1 and MLRs: A potential target for neuronal growth and neuroplasticity after ischemic stroke.Int J Med Sci. 2019 Oct 15;16(11):1492-1503. doi: 10.7150/ijms.35158. eCollection 2019. Int J Med Sci. 2019. PMID: 31673241 Free PMC article. Review.
-
Hydrogen-rich saline alleviates inflammation and apoptosis in myocardial I/R injury via PINK-mediated autophagy.Int J Mol Med. 2019 Sep;44(3):1048-1062. doi: 10.3892/ijmm.2019.4264. Epub 2019 Jul 3. Int J Mol Med. 2019. PMID: 31524220 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources